- Home
- AMGN vs NEE Comparison
AMGN vs NEE Comparison
Compare AMGN & NEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- NEE
- Stock Information
- Founded
- AMGN 1980
- NEE 1925
- Country
- AMGN United States
- NEE United States
- Employees
- AMGN N/A
- NEE N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- NEE Electric Utilities: Central
- Sector
- AMGN Health Care
- NEE Utilities
- Exchange
- AMGN Nasdaq
- NEE Nasdaq
- Market Cap
- AMGN 156.2B
- NEE 152.1B
- IPO Year
- AMGN N/A
- NEE N/A
- Fundamental
- Price
- AMGN $288.18
- NEE $70.59
- Analyst Decision
- AMGN Buy
- NEE Buy
- Analyst Count
- AMGN 21
- NEE 15
- Target Price
- AMGN $323.62
- NEE $83.73
- AVG Volume (30 Days)
- AMGN 3.2M
- NEE 15.1M
- Earning Date
- AMGN 05-01-2025
- NEE 07-23-2025
- Dividend Yield
- AMGN 3.30%
- NEE 3.21%
- EPS Growth
- AMGN 56.16
- NEE N/A
- EPS
- AMGN 10.94
- NEE 2.67
- Revenue
- AMGN $34,126,000,000.00
- NEE $25,269,000,000.00
- Revenue This Year
- AMGN $7.62
- NEE $13.53
- Revenue Next Year
- AMGN $1.88
- NEE $9.53
- P/E Ratio
- AMGN $26.34
- NEE $26.45
- Revenue Growth
- AMGN 15.56
- NEE N/A
- 52 Week Low
- AMGN $253.30
- NEE $61.72
- 52 Week High
- AMGN $346.85
- NEE $86.10
- Technical
- Relative Strength Index (RSI)
- AMGN 58.41
- NEE 53.30
- Support Level
- AMGN $269.10
- NEE $66.77
- Resistance Level
- AMGN $276.90
- NEE $68.37
- Average True Range (ATR)
- AMGN 5.90
- NEE 2.10
- MACD
- AMGN 2.48
- NEE -0.31
- Stochastic Oscillator
- AMGN 97.70
- NEE 59.22
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About NEE NextEra Energy Inc.
NextEra Energy's regulated utility, Florida Power & Light, is the largest rate-regulated utility in Florida. The utility distributes power to over 6 million customer accounts in Florida and owns 36 gigawatts of generation. FP&L contributes roughly 70% of NextEra's consolidated operating earnings. NextEra Energy Resources, the renewable energy segment, generates and sells power throughout the United States and Canada with more than 37 GW of generation capacity, including natural gas, nuclear, wind, and solar.